Gan & Lee Pharmaceuticals

• Founded

  1 Jan 1998

Sources: wikidata.org

• NCT07334496

  Phase 1, Not yet recruiting, 198 people, 12 Jan 2026

• NCT07150975

  Phase 3, Recruiting, 420 people, 2 Sept 2025

• A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid

  Phase 3, Recruiting, 240 people, 17 Jan 2025

• NCT06778967

  Phase 3, Active, not recruiting, 1,100 people, 16 Jan 2025

• NCT06737042

  Phase 2, Completed, 326 people, 17 Dec 2024

• NCT06670209

  Phase 1, Not yet recruiting, 32 people, 1 Nov 2024

• NCT06256549

  Phase 2, Status unknown, 272 people, 13 Feb 2024

• NCT03371108

  Phase 3, Completed, 567 people, 13 Dec 2017

• NCT03371082

  Phase 3, Completed, 576 people, 13 Dec 2017

Sources: clinicaltrials.gov

• Licence

  Menarini, 11 Aug 2026

• Financing

  18 Nov 2023

• IPO filing

  15 Jun 2020

Sources: static.cninfo.com.cn

• Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZETM-CN)

  Consulting or advice, Fees or honoraria, 14 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Combined Semaglutide and Sodium–Glucose Cotransporter 2 Inhibitors in Real-World Clinical Practice in China: Scholar Post Hoc Analysis

  ADA Scientific Sessions 2026 abstract, 5 Jun 2026